Il Dong Pharmaceutical Co Ltd - Asset Resilience Ratio
Il Dong Pharmaceutical Co Ltd (249420) has an Asset Resilience Ratio of 1.76% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Il Dong Pharmaceutical Co Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Il Dong Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Il Dong Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Il Dong Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Il Dong Pharmaceutical Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩10.11 Billion | 1.76% |
| Total Liquid Assets | ₩10.11 Billion | 1.76% |
Asset Resilience Insights
- Limited Liquidity: Il Dong Pharmaceutical Co Ltd maintains only 1.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Il Dong Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Il Dong Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Il Dong Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Il Dong Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.14% | ₩12.61 Billion ≈ $8.54 Million |
₩589.04 Billion ≈ $399.19 Million |
-2.44pp |
| 2023-12-31 | 4.58% | ₩28.02 Billion ≈ $18.99 Million |
₩611.26 Billion ≈ $414.24 Million |
+0.53pp |
| 2022-12-31 | 4.06% | ₩26.60 Billion ≈ $18.03 Million |
₩655.81 Billion ≈ $444.43 Million |
+1.36pp |
| 2021-12-31 | 2.69% | ₩19.09 Billion ≈ $12.94 Million |
₩708.97 Billion ≈ $480.46 Million |
+2.59pp |
| 2020-12-31 | 0.10% | ₩600.00 Million ≈ $406.61K |
₩605.28 Billion ≈ $410.19 Million |
-0.08pp |
| 2019-12-31 | 0.18% | ₩1.10 Billion ≈ $748.05K |
₩612.72 Billion ≈ $415.23 Million |
-0.12pp |
| 2018-12-31 | 0.30% | ₩1.70 Billion ≈ $1.15 Million |
₩564.67 Billion ≈ $382.67 Million |
+0.23pp |
| 2017-12-31 | 0.07% | ₩376.06 Million ≈ $254.85K |
₩564.63 Billion ≈ $382.64 Million |
+0.05pp |
| 2016-12-31 | 0.01% | ₩71.17 Million ≈ $48.23K |
₩550.35 Billion ≈ $372.97 Million |
-- |
About Il Dong Pharmaceutical Co Ltd
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central n… Read more